<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025441</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068961</org_study_id>
    <secondary_id>SIOP-MMT-98</secondary_id>
    <secondary_id>SFOP-SIOP-MMT-98</secondary_id>
    <secondary_id>CCLG-SIOP-MMT-98</secondary_id>
    <secondary_id>EU-20126</secondary_id>
    <secondary_id>STS-1998</secondary_id>
    <nct_id>NCT00025441</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors</brief_title>
  <official_title>MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Societe Internationale d'Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Societe Francaise Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the overall survival of children with metastatic rhabdomyosarcoma or other
           malignant mesenchymal tumors treated with one of two different chemotherapy regimens
           based upon risk group.

        -  Determine the role of low-intensity maintenance chemotherapy after intensive
           conventional chemotherapy in standard-risk children.

        -  Determine the value of a therapeutic window in high-risk children.

        -  Determine the role of sequential high-dose chemotherapy with peripheral blood stem cell
           transplantation in achieving complete response in high-risk children.

        -  Determine the complete response, overall survival, and event-free survival in high-risk
           children.

      OUTLINE: This is a multicenter study. Patients are stratified according to risk group
      (standard vs high).

      Standard-risk patients:

        -  Initial chemotherapy: Patients receive vincristine IV on day 1 for weeks 1-7. Patients
           also receive dactinomycin IV on day 1 and ifosfamide IV over 1 hour on days 1-3 of week
           1. Patients then receive carboplatin IV over 1 hour and epirubicin IV over 6 hours on
           day 1 of week 4. Patients then receive ifosfamide IV over 1 hour and etoposide IV over 4
           hours on days 1-3 of week 7. Treatment repeats every 8 weeks for 3 courses in the
           absence of disease progression or unacceptable toxicity. After the second course,
           patients with less than 50% partial response (PR) are removed from study.

      Patients with parameningeal disease undergo radiotherapy 5 days a week for about 8 weeks
      beginning at week 9.

        -  Maintenance chemotherapy: Patients receive cyclophosphamide IV over 1 hour, vincristine
           IV, and dactinomycin IV on day 1. Treatment repeats every 3 weeks for 9 courses in the
           absence of disease progression or unacceptable toxicity.

      Patients who remain in PR at week 17 undergo radiotherapy for about 9 weeks beginning at week
      18.

      High-risk patients:

        -  Initial chemotherapy: Patients receive window study drug carboplatin IV over 1 hour or
           doxorubicin on day 1. Treatment repeats every 3 weeks for 2 courses.

      Patients receive high-dose cyclophosphamide IV over 1 hour on days 1-3 of week 7. Beginning
      on day 8, patients receive filgrastim (G-CSF) IV or subcutaneously (SC) daily until day 13.
      Patients may undergo peripheral blood stem cell (PBSC) collection.

      Patients receive high-dose etoposide IV over 24 hours on days 15-17. Beginning on day 22,
      patients receive G-CSF IV or SC daily until day 27.

      Patients receive high-dose cyclophosphamide IV over 1 hour on days 29-31. Beginning on day
      36, patients receive G-CSF IV or SC daily until day 42. Patients may undergo PBSC collection
      if not previously performed. Patients who achieve complete response (CR) are removed from
      study.

      Patients receive high-dose carboplatin IV over 1 hour on days 44-48. Patients undergo PBSC
      reinfusion on day 52. Beginning on day 55, patients receive G-CSF IV or SC daily until blood
      counts recover.

        -  Maintenance chemotherapy: Patients receive maintenance chemotherapy comprising
           cyclophosphamide, vincristine, and dactinomycin in the same manner as the standard-risk
           patients.

      Patients with parameningeal disease and those not achieving CR undergo radiotherapy beginning
      at week 17. Patients achieving CR, unless metastatic disease is resected, undergo
      radiotherapy beginning on week 15.

      Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 6 months
      for 2 years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 8-30 standard-risk patients will be accrued for this study
      within 4 years. A total of 15-75 high-risk patients will be accrued for this study within 4-5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dactinomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic rhabdomyosarcoma or other malignant mesenchymal
             tumors

               -  Standard risk defined as:

                    -  Less than 10 years of age

                    -  No bone or bone marrow involvement

               -  High risk defined as:

                    -  At least 10 years of age OR

                    -  Bone or bone marrow involvement

          -  Diagnosed less than 8 weeks ago

          -  Previously untreated disease except for initial surgery within the past 8 weeks

        PATIENT CHARACTERISTICS:

        Age:

          -  6 months to under 18 years

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No prior endocrine therapy

        Radiotherapy:

          -  Concurrent radiotherapy allowed

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather P. McDowell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Liverpool Children's Hospital, Alder Hey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annabel B.M. Foot</last_name>
    <role>Study Chair</role>
    <affiliation>Bristol Royal Hospital for Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Bergeron</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children</name>
      <address>
        <city>Crumlin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meyerstein Institute of Oncology at University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010 Jun;46(9):1588-95. doi: 10.1016/j.ejca.2010.02.051. Epub 2010 Mar 24.</citation>
    <PMID>20338746</PMID>
  </results_reference>
  <verification_date>November 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>chondrosarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>fibrosarcomatous osteosarcoma</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
  <keyword>mixed childhood rhabdomyosarcoma</keyword>
  <keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>childhood malignant hemangiopericytoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood alveolar soft-part sarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood epithelioid sarcoma</keyword>
  <keyword>childhood malignant mesenchymoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

